{
    "clinical_study": {
        "@rank": "158174", 
        "arm_group": [
            {
                "arm_group_label": "Reference", 
                "arm_group_type": "Experimental", 
                "description": "single dose BI 691751"
            }, 
            {
                "arm_group_label": "Test", 
                "arm_group_type": "Experimental", 
                "description": "multiple doses of itraconazole + single dose BI 691751"
            }
        ], 
        "brief_summary": {
            "textblock": "Investigation of the relative bioavailability of a single dose of BI 691751 when given alone\n      and together with itraconazole; safety and tolerability"
        }, 
        "brief_title": "Interaction of BI 691751 With Itraconazole", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy male subjects\n\n          2. body mass index (BMI) of 18.5 to 29.9 kg/m2\n\n          3. Subjects must be able to understand and comply with study requirements\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including blood pressure (BP), pulse rate\n             (PR), or electrocardiogram (ECG)) deviating from normal and judged clinically\n             relevant by the investigator.\n\n          2. Pulse rate outside 45 to 100 bpm or repeated measurements of systolic BP outside 90\n             to 140 mmHg or diastolic BP outside 50 to 90 mmHg.\n\n          3. Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          4. Any alanine transaminase (ALT/GPT), aspartate transaminase (AST/GOT), or\n             gammaglutamyltransferase (GGT) value outside the reference range at the screening\n             examination\n\n          5. Any evidence of a concomitant disease judged clinically relevant by the investigator\n\n          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological, or hormonal disorders\n\n          7. Any history of relevant liver diseases such as disturbance of liver function,\n             jaundice, drug induced liver injury, Dubin-Johnson syndrome, Rotor syndrome, or liver\n             tumors"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044393", 
            "org_study_id": "1334.10", 
            "secondary_id": "2013-003814-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test", 
                "description": "multiple doses of itraconazole given as capsules", 
                "intervention_name": "itraconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test", 
                "description": "single dose BI 691751 given as tablet", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference", 
                "description": "single dose BI 691751 given as tablet", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1334.10.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Relative Bioavailability of a Single Oral Dose of BI 691751 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-tz (area under the concentration-time curve of BI 691751 in plasma and whole blood over the time interval from 0 up to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "31 days postdose"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte of BI 691751 in plasma and whole blood)", 
                "safety_issue": "No", 
                "time_frame": "31 days postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044393"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 extrapolated to infinity)", 
            "safety_issue": "No", 
            "time_frame": "31 days postdose"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}